Welcome to our dedicated page for Canopy Growth SEC filings (Ticker: CGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ever tried locating Canopy Growth’s biological asset valuations or U.S. THC exposure in a 300-page report? The company’s cannabis regulations, fair-value accounting and brand acquisitions make each disclosure dense. That’s why this page does more than list documents—it turns the tough parts of Canopy Growth SEC filings explained simply.
Every form—whether a Canopy Growth quarterly earnings report 10-Q filing or a sudden Canopy Growth 8-K material events explained—arrives here within seconds of hitting EDGAR. Stock Titan’s AI instantly produces plain-English summaries, highlights cash-flow turning points and links note references so you can move from headline to footnote without scrolling hundreds of pages. Need to monitor management moves? Our alert engine captures Canopy Growth Form 4 insider transactions real-time, flagging each Canopy Growth executive stock transactions Form 4 alongside price and option data.
Use the annual report to see cultivation capacity; the proxy to unpack Canopy Growth proxy statement executive compensation; or dive into segment margins with our Canopy Growth earnings report filing analysis. If you are tracking regulatory risk, the system groups risk-factor language across years so understanding Canopy Growth SEC documents with AI becomes a two-minute task. Investors, analysts and portfolio managers rely on these tools to answer questions like “What did management say about U.S. legalization timing?� or “Were there new goodwill impairments?”—all without manual page hunts. From the first Canopy Growth insider trading Form 4 transactions alert to a fully indexed Canopy Growth annual report 10-K simplified, every disclosure is refined for faster, smarter decision-making.
Canopy Growth Corporation filed a Form 8-K dated 8 Aug 2025. Under Item 2.02, the company furnished (not filed) a press release detailing fiscal Q1 FY26 results for the quarter ended 30 Jun 2025; the actual financial figures are contained in Exhibit 99.1 and are not included in this filing.
Under Item 5.02, the board appointed Margaret Shan Atkins as an independent director, effective 6 Aug 2025, and named her to the audit committee. The filing states there are no related-party transactions, and Ms. Atkins will receive standard director compensation and a customary indemnification agreement. No other material events, transactions or guidance updates are disclosed.
CGC Q1 FY26 (quarter ended 30 Jun 2025) highlights:
- Net revenue rose 9% YoY to CA$72.1 m (CA$66.2 m LY) as adult-use, medical and accessories sales grew.
- Gross margin fell to 25% (CA$18.0 m) from 35% (CA$23.0 m) on higher COGS and CA$1.9 m inventory write-downs.
- Operating loss narrowed to CA$22.6 m vs. CA$29.1 m; net loss improved sharply to CA$41.5 m (CA$129.2 m LY) as prior-year period contained CA$93.9 m fair-value and debt-settlement charges.
- Cash burn: operating cash outflow cut to CA$10.3 m (CA$51.8 m). FCF benefited from lower restructuring and working-capital release.
- Liquidity: cash & equivalents up to CA$126.2 m (CA$113.8 m at Mar-25) aided by CA$38.3 m raised under Feb-25 ATM program. Short-term investments CA$17.4 m.
- Leverage: total debt reduced to CA$295.3 m (CA$304.1 m), with current portion CA$6.3 m. Credit-facility balance shrank after ongoing discounted repurchases.
- Equity: book value CA$489.0 m; accumulated deficit widened to CA$10.97 bn.
- Canopy USA deconsolidated (effective Apr-24) creating CA$5.0 m gain and recognition of equity-method investments and CA$142.4 m Elevate loan receivable.
- Management states substantial-doubt concerns are "alleviated" via equity raises, debt pay-downs and ongoing cost actions, but continues to evaluate further financing.
Per-share: basic loss CA$0.22 vs CA$1.60 as share count rose to 188.3 m (79.2 m LY) due to ATM and acquisition-related issuances.
Canopy Growth’s 2025 DEF 14A outlines four voting items for the 26-Sep-2025 virtual AGM:
- Election of five directors (four incumbents plus new nominee Joe Bayern). Independent directors would remain 80% of the board; David Lazzarato continues as independent chair.
- Re-appointment of PKF O’Connor Davies LLP as auditor for FY 2026.
- A special resolution authorising a 5-for-1 to 15-for-1 reverse share split at the board’s discretion before 26-Sep-2026 to restore compliance with stock-exchange price requirements.
- Advisory “say-on-pay� approval of FY 2025 executive compensation.
Governance & policy highlights: the board refreshed seven key policies (Disclosure, Insider-Trading, Regulation FD, Anti-Bribery, Clawback, Code of Business Conduct, Disclosure Compliance) and offered four director-education sessions.
Compensation: New CEO Luc Mongeau’s package—C$975k salary, 100% STI target, 300% LTI mix (50% options/50% RSUs) plus a one-time 225k option/50k RSU sign-on grant—reflects a scaled structure versus former CEO David Klein, whose salary was cut to US$750k and whose outstanding equity will be forfeited on retirement (31-Aug-2025). FY 2025 NEO cash bonuses paid at 77.6% of target as only 17.6% of EBITDA and 29.3% of revenue targets were met.
Shareholder logistics: record date 1-Aug-2025; proxies due 24-Sep-2025. All participation and voting will be via live audio webcast.
FAQ
What is the current stock price of Canopy Growth (CGC)?
What is the market cap of Canopy Growth (CGC)?
